Serving Overlooked PatientsSM

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about FerabrightTM

Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about JavadinTM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about FerabrightTM

Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about JavadinTM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

OUR PRODUCTS

Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.

News & Events

Azurity Pharmaceuticals Announces FerabrightTM (ferumoxytol injection) Now Available in the U.S. for Magnetic Resonance Imaging of the Brain

Woburn, MA — February 26, 2026 — Azurity Pharmaceuticals, Inc. announced today that FerabrightTM (ferumoxytol injection) is now available in the U.S. Ferabright is the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1 Ferabright was approved by the U.S. Food and Drug Administration (FDA) in October 2025.

read more

Azurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII

Woburn, MA—February 10, 2026—Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available mid-2026 for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.

read more
Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Show details Hide details
Functional, Preference, Performance and Analytics Tracking Technologies or Statistics Cookies

The following Tracking Technologies allow us, among other things, to count Website visits and traffic sources so that we can measure and improve the performance of our Website. They help us to know which pages are the most – and least – popular, and see how visitors move around the Website. If you do not allow these Tracking Technologies, we will not know when you have visited our Website, and we will not be able to monitor our Website’s performance.

The following Tracking Technologies also enable the Website to provide enhanced functionality and personalization. They may be used by us or by third-party providers whose services we have added to our pages. If you do not allow these Tracking Technologies, then some or all of these services may not function properly.

Show details Hide details
Targeting Tracking Technologies

The following Tracking Technologies may be used on our Website by our advertising partners (or set directly by our advertising partners) to collect data about your online activity. They record your visits to our Website, the pages you have visited, and the links you have followed. They are used by our advertising partners to build a profile of your interests and show you relevant advertisements on our Website as well as other sites. For example, they're used to detect when you click on an ad and show you ads based on your social media interests and browsing history.

We and third parties use social media cookies to show you ads and content based on your social media profiles and activity on our Website. They’re used to connect your activity on our Website to your social media profiles so the ads and content you see on our Website and on social media will better reflect your interests.

If you do not allow these Tracking Technologies, you will experience fewer targeted advertisements, and you will impair our ability to provide you with tailored services and offerings.

Show details Hide details